|
Eligard® is a prescription medication for the palliative treatment of advanced prostate cancer.
On October 1, 2009, QLT Inc. announced that it completed the sale of all of the shares of its wholly-owned U.S. subsidiary, QLT USA, Inc. to TOLMAR Holding, Inc. QLT USA’s principal operating asset was the Eligard line of products for the treatment of prostate cancer.
For more information on Eligard, please refer to the Eligard website.
|
